SCHEDULE 13G/A: BlackRock Discloses 7.6% Passive Stake in ZEVRA THERAPEUTICS
Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in ZEVRA THERAPEUTICS, INC. as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 4,080,420 shares of ZEVRA THERAPEUTICS, INC. common stock.
- This ownership represents 7.6% of the total outstanding common stock of ZEVRA THERAPEUTICS, INC.
- BlackRock holds sole voting power over 4,027,153 shares and sole dispositive power over 4,080,420 shares.
- The filing was made under Rule 13d-1(b), indicating a passive investment, and certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- BlackRock, Inc. is classified as a parent holding company for the purpose of this filing.
- BlackRock Investment Management, LLC, a subsidiary of BlackRock, Inc., is specifically noted as beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine ownership disclosure with no specific positive or negative operational or financial news.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of institutional ownership and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- No direct impact on customers, suppliers, or creditors is indicated by this ownership disclosure.
- Shareholders may note the significant institutional ownership by BlackRock, which can imply a degree of confidence in the company, though this is a passive stake.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney that was revoked by the new one. |
| 2024-12-31 | Date of the event which requires the filing of this statement (reporting period end date). |
| 2025-01-21 | Date of execution for the new Power of Attorney. |
| 2025-02-05 | Date of filing of the Schedule 13G Amendment No. 1. |
Keywords
BlackRock, ZEVRA THERAPEUTICS, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.